Welcome to our dedicated page for Amrize SEC filings (Ticker: AMRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amrize Ltd (NYSE: AMRZ) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. As a Switzerland-incorporated issuer listed on the New York Stock Exchange and the SIX Swiss Exchange, Amrize files reports with the U.S. Securities and Exchange Commission that give investors structured information about its operations and financial condition.
Recent Form 8-K filings from Amrize have reported quarterly financial results and related investor materials. These filings typically reference earnings press releases and investor presentations that discuss revenue by segment, non-GAAP metrics such as Adjusted EBITDA, Free Cash Flow, Net Debt and Net Leverage Ratio, and commentary on the performance of the Building Materials and Building Envelope segments. They also confirm details such as the company’s jurisdiction of incorporation in Switzerland and its principal executive office location in Zug.
On this page, investors can monitor new 8-K filings as they are released, along with other SEC forms when available, such as annual and quarterly reports that provide more comprehensive detail on Amrize’s business, risk factors and segment information. Filings related to capital structure, such as debt issuance, and any documents reporting significant events or transactions, are also part of the regulatory record.
Stock Titan enhances these filings with AI-powered summaries designed to explain the main points of lengthy documents in clear language. This can help readers quickly understand key topics such as segment performance, changes in leverage, major investments, or strategic initiatives like the ASPIRE program, while still allowing direct access to the full original filings for detailed analysis.
Amrize Ltd reported that Chief Strategy & M&A Officer Samuel Jonas Poletti acquired 4,256 ordinary shares on a grant/award basis at no cost. The shares were issued upon settlement of performance stock units originally granted under Holcim Ltd equity awards converted in connection with the Amrize spin-off. Following this settlement, his directly held stake increased to 7,645 ordinary shares.
Amrize Ltd reported that Chief Technology Officer Roald Brouwer acquired 4,257 ordinary shares on a grant or award basis at a stated price of $0.00 per share. After this settlement, his directly held stake totals 13,257 ordinary shares.
The new shares reflect settlement of performance stock units that originated from Holcim Ltd equity incentives, which were converted in connection with the June 23, 2025 spin-off of Amrize from Holcim. These units vested based on the performance of Holcim and Amrize over the period from January 1, 2023 through December 31, 2025.
Amrize Ltd Chief Marketing & Corporate Affairs Officer Forrest Nollaig reported routine equity compensation activity involving the company’s ordinary shares. On February 27, 2026, Nollaig acquired 11,157 ordinary shares at $0.00 per share through the settlement of performance stock units originally granted under Holcim Ltd incentive awards and converted in connection with the Amrize spin-off.
On the same date, 4,681 ordinary shares were disposed of in a tax-withholding disposition at $64.99 per share to cover exercise price or tax obligations, rather than an open-market sale. After these transactions, Nollaig directly held 18,139 Amrize ordinary shares, which include 258 shares acquired under the Amrize Ltd 2025 Employee Stock Purchase Plan on December 31, 2025.
Amrize Ltd Chief Supply Chain Officer Mario Gross reported an equity award settlement that increased his direct holdings. On this Form 4, he acquired 4,257 Amrize ordinary shares at a stated price of $0.00 per share through the settlement of performance stock units.
After this grant, his direct ownership rose to 27,747 ordinary shares. The settled units stemmed from performance stock awards originally granted by Holcim Ltd and converted in connection with the June 23, 2025 spin-off of Amrize, with vesting based on the performance of both Holcim and Amrize from January 1, 2023 through December 31, 2025. His holdings also include 258 shares obtained under the Amrize Ltd 2025 Employee Stock Purchase Plan on December 31, 2025.
Amrize Ltd President, Building Materials, Jaime Hill reported equity transactions in Amrize ordinary shares. Hill received a grant/award acquisition of 6,385 shares at no cost, reflecting settlement of performance stock units tied to Holcim and Amrize performance through December 31, 2025. In a related tax-withholding disposition, 1,928 shares were delivered at $64.99 per share to cover tax obligations. After these transactions, Hill directly owns 22,816 Amrize ordinary shares, including 258 shares acquired under the Amrize Ltd 2025 Employee Stock Purchase Plan on December 31, 2025.
Amrize Ltd Chief Financial Officer Ian A. Johnston reported compensation-related share movements in Amrize ordinary shares. On February 27, 2026, he acquired 4,257 shares at a price of $0.00 per share through the settlement of performance stock units tied to Holcim and Amrize performance from January 1, 2023 to December 31, 2025. On the same date, 1,941 shares were disposed of at $64.99 per share to satisfy tax obligations, leaving him with 20,860 shares owned directly.
Amrize Ltd reported that Chairman and CEO Jenisch Jan Philipp acquired new equity awards on February 27, 2026. He received a grant of 620,715 stock options and 138,582 ordinary shares at a price of
The footnotes explain these awards stem from performance stock units and options originally granted by Holcim Ltd and converted in connection with the Amrize spin-off. Performance was measured over multi‑year periods through
Amrize Ltd is soliciting shareholder votes at its 2026 Annual General Meeting to be held physically on
The agenda includes an advisory say-on-pay vote and a vote on frequency (the Board recommends every one year), approval of the Swiss Statutory Remuneration Report, the Non-Financial Matters Report, and the offsetting of accumulated losses. The Board proposes a special distribution of up to
Other items include re-election of nine directors, approval of maximum aggregate Board compensation of
Amrize Ltd Chief Financial Officer buys additional shares. Ian A. Johnston purchased a total of 1,200 Ordinary Shares of Amrize Ltd in open-market transactions on
Amrize Ltd changed its independent auditor, appointing Ernst & Young LLP (EY US) as its independent registered public accounting firm for the year ending December 31, 2026, including interim reviews beginning with the period ending March 31, 2026. On the same date, the audit committee dismissed Ernst & Young AG (EY Switzerland) from this role, while EY Switzerland will continue as statutory auditor under Swiss law. The company links this shift to its post–spin-off focus on North American operations. EY Switzerland’s prior reports on the company’s combined financial statements for 2022–2024 contained no adverse opinions, disclaimers, or qualifications, and the company reports no disagreements or reportable events other than a previously disclosed material weakness in internal control over financial reporting related to insufficient U.S. GAAP–experienced personnel.